Dr. Sgourakis’ research focuses on understanding the intricate molecular mechanisms that determine the vast repertoire of peptide antigens displayed by the proteins of the Major Histocompatibility Complex for immune surveillance by T cells and Natural Killer cells.
Dr. Xing is the Executive Director of the Department of Biomedical and Health Informatics, the Francis West Lewis Chair and director of the Center for Computational and Genomic Medicine at CHOP, and professor of Pathology and Laboratory Medicine at the University of Pennsylvania. His research focuses on computational biology and genomics of RNA processing and regulation.
Dr. Barret's research program focuses on immune function of children with cancer. His research involves investigating possible immune deficiencies that result in children developing cancer and developing immune-based therapies for childhood cancer.
Dr. Weber is developing approaches to enhance CAR-T cell therapies for pediatric cancer by reprogramming T cells with improved durability and exhaustion resistance. His work will uncover molecular mechanisms that promote CAR-T cell exhaustion and identify new targets for therapeutic intervention.
John M. Maris, MD, is leading a pediatric immuno-oncology Center for Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers with support from the NCI Moonshot Initiative.
Yi Xing, PhD, an internationally prominent scientist in computational biology and genomics, will join Children’s Hospital of Philadelphia (CHOP) on Sept. 1 to establish a new center dedicated to harnessing big data and genomic technologies in discovering new treatment approaches for children’s health.
"Bold" is perhaps the best word to describe this week's roundup of Research Institute news, as Children's Hospital of Philadelphia nurses and investigators alike made headlines for their experimental work in pediatric CAR T-cell therapy: a cancer-fighting immunotherapy treatment that aims to re-engineer a patient's own T cells to detect and destroy tumor cells.
The Mechanistic Molecular Immunology Lab integrates cutting-edge structural biology and biochemistry tools with functional immunoassays to understand the molecular basis of immune responses to viral infections and tumors, with an emphasis on the development of novel protein-based therapeutics.
Yi Xing, PhD is Executive Director of the Department of Biomedical and Health Informatics. Dr. Xing’s groundbreaking research fits well with DBHi’s mission by merging the fields of computational biology, biomedical data science, RNA genomics, human genetics, precision medicine, and immuno-oncology. He is one of the premier investigators in this space, playing a pivotal role in developing new genomic technologies and computational methods, and leading collaborative studies aimed at understanding how the human genome and its gene products contribute to development and disease. He has an extensive publication record in bioinformatics, genomics, and RNA biology and is recognized internationally for his expertise in the fields of computational and experimental RNA biology.